TMS & tES Drug-Device Pipeline — PatSnap Eureka
TMS & Electrical Stimulation Drug-Device Pipeline in Depression & Cognitive Disorders
Pharmacotherapy leaves 40% or more of depression patients without adequate relief. Explore the full patent and clinical evidence landscape for rTMS, tDCS, tACS, and DBS — from FDA-approved protocols to emerging personalized neuromodulation strategies.
Modality Development Stage
Pipeline maturity across six neuromodulation approaches for depression and cognitive disorders
From DLPFC to Subcallosal Cingulate: The Neural Circuit Map of Depression
Major depressive disorder (MDD) and treatment-resistant depression (TRD) are the primary indication categories driving device-based neuromodulation research. The left dorsolateral prefrontal cortex (DLPFC) is the most frequently cited stimulation target across rTMS, tDCS, and TMS/EEG-guided protocols, reflecting its role as a hub in frontolimbic circuits disrupted in depression. Research published by PatSnap's life sciences intelligence platform aggregates these signals across global patent and literature databases.
The subgenual anterior cingulate cortex (sACC / Brodmann area 25) is identified as a key target for deeper modalities. Prefrontal cortex sites with direct fiber connections to the sACC are particularly effective for TMS-based antidepressant therapy, with two neuroimaging datasets linking sACC connectivity with optimal PFC stimulation coordinates.
At the molecular level, brain-derived neurotrophic factor (BDNF) is a key downstream mediator of rTMS antidepressant effects, reported as a translational biomarker in clinical trials. GABAergic pathways are also implicated: short-interval cortical inhibition (SICI), reflecting GABAA receptor-mediated activity, and cortical silent period (CSP), reflecting GABAB activity, are both reduced in MDD patients as evidenced in a systematic review and meta-analysis from Keio University.
Thalamocortical oscillatory networks constitute an additional mechanistic target: rTMS entrains and resets thalamocortical oscillators and restores normal alpha/theta band dynamics. Neurotransmitter modulation — specifically dopaminergic, serotonergic, and glutamatergic pathways — is discussed across multiple retrieved papers, with N-acetyl aspartate (NAA), glutamate (Glu), and glutamine (Gln) levels in the left DLPFC measured via MR spectroscopy as pharmacodynamic readouts. Cognitive targets are also prominent: hippocampal neurogenesis and synaptic plasticity (LTP/LTD mechanisms) are substrates for rTMS-driven cognitive recovery. The National Institute of Mental Health recognizes neuromodulation as a priority research area for treatment-resistant conditions.
Six Neuromodulation Approaches Across the Invasiveness Spectrum
From FDA-approved rTMS protocols to investigational DBS targets — a synthesis of patent and academic literature evidence covering the full pipeline.
Repetitive TMS (rTMS) — High-Frequency & Standard Protocols
Standard protocols involve 10 Hz stimulation delivered to the left DLPFC over 4–6 weeks. FDA-approved for MDD in patients with medication failure. Mechanistically, high-frequency rTMS depolarizes cortical neurons and modulates prefrontal-limbic circuits with downstream effects on BDNF, serotonin, dopamine, and synaptic plasticity. Low-frequency rTMS (1 Hz) to the right DLPFC suppresses cortical excitability as an alternative protocol. Continuous theta-burst stimulation (cTBS) and intermittent theta-burst stimulation (iTBS) are accelerated variants with comparable efficacy in shorter sessions.
Investigational: cognitive disorders, PTSD, OCD, schizophreniaDeep TMS (dTMS) — Brainsway H-Coil Technology
The Brainsway H1-coil system stimulates neuronal pathways deeper than those accessible by conventional figure-of-eight coils, reaching deeper subcortical structures relevant to mood regulation. An H5 coil variant for deep rTMS in Parkinson syndromes uses sequential 1 Hz primary motor cortex stimulation and bilateral 10 Hz prefrontal cortex stimulation, as described in real-world German data from the University of Rostock (2022). The H1-coil dTMS system is described as a separately approved device from standard rTMS.
Investigational: OCD, Parkinson-spectrum disordersEEG-Synchronized & Personalized TMS (sTMS / IT-TMS)
NeoSync, Inc. developed a synchronized TMS (sTMS) device delivering sinusoidal stimulation at the individual alpha frequency (IAF), tested in a randomized, sham-controlled pilot study (NCT01683019, n=46) for MDD. Individual target-TMS (IT-TMS) guided by resting-state fMRI functional connectivity maps is described in a Chinese cohort of MDD patients with suicidal ideation. EEG-guided biomarker selection for personalization is an area of active development. PatSnap's IP analytics tools help track emerging personalization IP.
EEG-guided biomarker selection actively developingTranscranial Direct Current Stimulation (tDCS)
tDCS modulates cortical excitability via low-intensity direct current (typically 1–2 mA) applied through scalp electrodes. Anodal stimulation of the left DLPFC produces excitatory effects. Applied in MDD, schizophrenia, autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), and Parkinson's disease. Its utility is described as limited by weak effect sizes and high inter-individual variability. The excitation/inhibition (E/I) balance framework positions tDCS as a potential therapy for neurodevelopmental disorders. Combination with antidepressants and cognitive therapy is explored in clinical trials. The WHO identifies treatment-resistant depression as a global priority.
Combination trials with antidepressants ongoingTranscranial Alternating Current Stimulation (tACS)
tACS applies sinusoidal currents to entrain neural oscillations at specific frequencies. High-definition tACS and bifocal tACS are two variants with high application potential — the former targeting local oscillations, the latter modulating inter-area functional connectivity. tACS is entering early psychiatric clinical trials, with mechanisms involving both synaptic long-term plasticity and entrainment of disease-relevant oscillatory bands. Described as an emerging direction rather than an established modality.
Emerging: early psychiatric clinical trialsDeep Brain Stimulation (DBS) — Refractory Psychiatric & Cognitive Conditions
DBS represents the invasive tier, targeting subcortical structures including the subcallosal cingulate gyrus (Brodmann area 25), ventral capsule/ventral striatum (VC/VS), nucleus accumbens (NA), inferior thalamic peduncle (ITP), and anterior limb of the internal capsule/bed nucleus of the stria terminalis (IC/BST). Open-label studies have reported benefit in up to 90% of TRD patients, but randomized controlled trial response rates have been lower, with surgical variability implicated. FDA-approved for PD, essential tremor, and dystonia; investigational under humanitarian device exemption for TRD and OCD.
FDA-approved: PD, essential tremor, dystoniaKey Molecular Targets & Biomarker Evidence
Patent and literature signals across neurophysiological targets and clinical trial endpoints in the TMS/tES depression pipeline.
Molecular & Circuit Targets: Evidence Density
Relative frequency of target citation across retrieved patent and literature records, with DLPFC dominating the dataset.
Pipeline by Invasiveness Tier
Distribution of identified neuromodulation modalities across non-invasive, minimally invasive, and invasive tiers in the retrieved dataset.
Academic-Dominant IP Landscape with Targeted Commercial Filings
Innovation activity in this dataset is heavily skewed toward academic and clinical research publications, with only two explicit patent filings identified — signalling a pre-commercial or distributed-IP phase for non-invasive modalities.
University of California System
Multiple papers spanning mechanisms, biomarkers, and clinical outcomes in MDD — from UC Irvine (thalamocortical oscillations, 2013), UCLA (rTMS + chronic pain biomarkers, 2021), UC San Diego (Brainsway H1-coil dTMS, 2016), and UC Davis (tDCS roadmap, 2019). One of the highest-volume institutional contributors in the retrieved dataset.
Chinese Academic Institutions
Among the highest-volume contributors, particularly for clinical rTMS trials in MDD and cognitive disorders. Includes Xijing Hospital/Fourth Military Medical University (rTMS mechanisms, 2018), Xi'an Jiaotong University (IT-TMS for suicidal ideation, 2021), Chinese University of Hong Kong (neuronavigated rTMS in major neurocognitive disorder, 2020), Guangzhou Medical University, and Jilin University.
Krembil Research Institute / Toronto Western
EEG biomarkers and therapeutic TMS response — including a 2022 systematic review of resting and TMS-EEG markers of treatment response in MDD, and a 2015 paper on TMS for neurodegenerative disease pathophysiology. Key node in the EEG-guided personalization research cluster.
Brigham & Women's / Harvard Medical School
Circuit-targeted TMS and DBS network identification for depression, addiction, PTSD, and multiple sclerosis (2023). Represents the most recent high-impact institutional contribution in the dataset, focusing on transdiagnostic circuit mapping as a framework for precision neuromodulation. Explore the full PatSnap customer landscape for similar research organizations.
From Pilot Studies to Randomized Controlled Trials
Retrieved results contain multiple explicit clinical signals spanning FDA-approved protocols through emerging biomarker-guided trials. The FDA-approved indication for rTMS covers prefrontal 10 Hz left DLPFC stimulation over 4–6 weeks for MDD in patients failing medication. A single-blind, sham-controlled RCT (n=58) of 10 Hz neuronavigated rTMS over 3 weeks evaluated depressive symptoms, global cognitive function, and serum BDNF in patients with major neurocognitive disorder (dementia with depression) — a directly translational signal bridging depression and cognitive disorder indications, from the Chinese University of Hong Kong (2020).
A trial of 23 patients with comorbid MDD and PTSD receiving therapeutic TMS used EEG spectral event analysis as a biomarker readout, linking transient oscillatory events to clinical outcomes (Providence VA/Butler Hospital, 2021). A separate randomized sham-controlled trial enrolled 61 treatment-resistant depression patients comparing prolonged iTBS, 10 Hz rTMS, and sham, with EEG theta-alpha biomarker readouts (National Central University, Taiwan, 2021).
A 54-patient RCT evaluated a miniaturized rTMS device (15 days, 10 Hz, 60 trains) versus standard and sham conditions, demonstrating significant Hamilton Depression Rating Scale reductions. This miniaturization signal is notable for its implications for at-home or ambulatory neuromodulation delivery. The FDA's device regulatory pathway continues to shape the clinical development landscape for these modalities. Track all active trials and patent filings through PatSnap's analytics platform.
DBS Target Landscape & Stimulation Engineering Directions
From subcortical anatomical targets in TRD to non-regular pulse patterning — the patent-disclosed engineering frontier of neuromodulation.
DBS Anatomical Targets for Treatment-Resistant Depression
Subcortical targets identified across retrieved DBS literature for TRD, from the most established (sACC/Area 25) to emerging targets.
Personalized TMS Protocol Development Pathway
From baseline neuroimaging to individualized stimulation delivery — the emerging IT-TMS and sTMS clinical workflow.
TMS & Electrical Stimulation Pipeline — Key Questions Answered
The left dorsolateral prefrontal cortex (DLPFC) is the most frequently cited stimulation target across rTMS, tDCS, and TMS/EEG-guided protocols, reflecting its role as a hub in frontolimbic circuits disrupted in depression. High-frequency rTMS (10 Hz) and anodal tDCS over this region are linked to antidepressant effects mediated by prefrontal-subcortical circuit normalization.
Yes. rTMS (prefrontal, 10 Hz, left DLPFC, 4–6 weeks) is confirmed as FDA-approved for MDD in patients failing medication. The Brainsway H1-coil dTMS system is described as a separately approved device.
Brain-derived neurotrophic factor (BDNF) is reported as a translational biomarker in clinical trials. GABAergic pathways are also implicated: short-interval cortical inhibition (SICI), reflecting GABAA receptor-mediated activity, and cortical silent period (CSP), reflecting GABAB activity, are both reduced in MDD patients. N-acetyl aspartate (NAA), glutamate (Glu), and glutamine (Gln) levels in the left DLPFC are measured via MR spectroscopy as pharmacodynamic readouts.
DBS targets subcortical structures including the subcallosal cingulate gyrus (Brodmann area 25), ventral capsule/ventral striatum (VC/VS), nucleus accumbens (NA), inferior thalamic peduncle (ITP), and anterior limb of the internal capsule/bed nucleus of the stria terminalis (IC/BST). Open-label studies have reported benefit in up to 90% of TRD patients, but randomized controlled trial response rates have been lower, with surgical variability implicated.
tDCS modulates cortical excitability via low-intensity direct current (typically 1–2 mA) applied through scalp electrodes, with anodal stimulation producing excitatory effects. tACS applies sinusoidal currents to entrain neural oscillations at specific frequencies, with mechanisms involving both synaptic long-term plasticity and entrainment of disease-relevant oscillatory bands. High-definition tACS targets local oscillations while bifocal tACS modulates inter-area functional connectivity.
tACS is described as entering early psychiatric clinical trials. It is characterized as preclinical to early clinical and described as an emerging direction rather than an established modality.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About TMS PatentsAccelerate Your Neuromodulation Pipeline Research
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Search patents, clinical literature, and biomarker signals across rTMS, tDCS, tACS, and DBS in one AI-native platform.
References
- Mechanism of Repetitive Transcranial Magnetic Stimulation for Depression — Xijing Hospital / Fourth Military Medical University (2018)
- High-Frequency Neuronavigated Repetitive Transcranial Magnetic Stimulation for Depression in Major Neurocognitive Disorder — Chinese University of Hong Kong (2020)
- Transcranial magnetic stimulation neurophysiology of patients with major depressive disorder — Keio University (2020)
- The relationship between brain oscillatory activity and therapeutic effectiveness of TMS in MDD — University of California Irvine (2013)
- Evaluation of Transcranial Magnetic Stimulation Efficiency in MDD Patients: A Magnetic Resonance Spectroscopy Study — Inonu University (2019)
- Anatomical Connectivity-Based Strategy for Targeting TMS as Antidepressant Therapy — International Joint Research Laboratory for Psychiatry and Neuroscience of Henan (2020)
- Use of Transcranial Magnetic Stimulation for Depression — Manhattan Psychiatric Center (2019)
- Cortical Plasticity Mechanism and Efficacy Prediction of cTBS in Depression — Yuyao City Third People's Hospital (2022)
- Repetitive TMS treatment of MDD and comorbid chronic pain: response rates and neurophysiologic biomarkers — UCLA / Semel Institute (2021)
- Treating Clinical Depression with Repetitive Deep TMS Using the Brainsway H1-coil — UC San Diego (2016)
- Safety of Deep Repetitive TMS against Medical Refractory Symptoms in Parkinson Syndromes — University of Rostock (2022)
- A pilot study of EEG-based synchronized TMS (sTMS) for treatment of Major Depression — NeoSync, Inc. (2014)
- Clinical Response of MDD Patients With Suicidal Ideation to Individual Target-TMS — Xi'an Jiaotong University (2021)
- Resting and TMS-EEG markers of treatment response in MDD: A systematic review — Krembil Research Institute / University Health Network (2022)
- Application of tDCS to psychiatric disorders: trends and perspectives — National Center of Neurology and Psychiatry, Tokyo (2015)
- Recent Trends in the Use of Electrical Neuromodulation in Parkinson's Disease — University College London (2018)
- tDCS as an Approach to Mitigate Neurodevelopmental Disorders Affecting Excitation/Inhibition Balance — University of Coimbra (2022)
- tACS for the treatment of MDD: from basic mechanisms toward clinical applications — Zhejiang University (2023)
- tACS: from basic mechanisms towards first applications in psychiatry — Justus-Liebig University Giessen (2020)
- Deep Brain Stimulation for Treatment-Resistant Depression: Review of the Literature (2015)
- Deep brain stimulation for treatment-resistant MDD: a comparison of two targets and long-term follow-up — KU Leuven (2017)
- Deep brain stimulation for psychiatric disorders: From focal brain targets to cognitive networks — University of Minnesota (2021)
- Transient neural oscillations reveal new biomarkers for therapeutic TMS for comorbid MDD and PTSD — Providence VA / Butler Hospital (2021)
- Critical role of rhythms in prefrontal TMS for depression: A randomized sham-controlled study — National Central University, Taiwan (2021)
- Targeting brain circuits across disorders — Brigham and Women's Hospital / Harvard Medical School (2023)
- Possible Mechanisms Underlying the Therapeutic Effects of TMS — Moscow Institute of Physics and Technology (2015)
- Transcranial Magnetic Stimulation and Cognitive Impairment — Paracelsus Medical University Salzburg (2018)
- National Institute of Mental Health — Brain Stimulation Therapies
- World Health Organization — Depression and Treatment-Resistant Conditions
- U.S. Food and Drug Administration — Neurological Device Regulatory Guidance
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This page represents a snapshot of innovation signals within the retrieved dataset only and should not be interpreted as a comprehensive view of the full clinical pipeline, regulatory landscape, or global IP landscape.
PatSnap Eureka searches patents and research to answer instantly.